Skip to main content

Advertisement

SpringerLink
Log in

Serum appearance of anti-p53 antibody in triple negative breast cancer

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

Significance of serum appearance of anti-p53 antibody in breast cancer has not been discussed fully.

Methods

The relationship between serum appearance of anti-p53 antibody and the clinicopathological features was investigated on the basis of the data of 42 women with breast cancer who had been treated with surgical resection.

Results

The proportion of tumors with histological grade 3 was significantly higher among tumors with serum appearance of anti-p53 antibody (P = 0.020). The proportion of triple negative tumors was also significantly higher among tumors with serum appearance of anti-p53 antibody (P = 0.003).

Conclusions

Preoperative appearance of anti-p53 antibody in sera can be correlated with the incidence of triple negative breast cancer and could therefore help identify tumors with aggressive potential.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutation in human cancers. Science. 1991;253:49–53.

    Article  PubMed  CAS  Google Scholar 

  2. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer. 1994;57:1–9.

    Article  PubMed  CAS  Google Scholar 

  3. Forslund A, Kressner U, Lindmark G, Inganas M, Lundholm K. Serum anti-p53 in relation to mutations across the entire translated p53 gene in colorectal carcinomas. Int J Oncol. 2001;19:501–6.

    PubMed  CAS  Google Scholar 

  4. Shimada H, Shiratori T, Takeda A, Matsushita K, Okazumi S, Akutsu Y, et al. Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg. 2009;33:272–7.

    Article  PubMed  Google Scholar 

  5. Nozoe T, Yasuda M, Honda M, Inutsuka S, Korenaga D. Clinicopathologic significance in serum presence of anti-p53 antibody in patients with colorectal carcinoma. Hepatogastroenterology. 2007;54:1422–5.

    PubMed  CAS  Google Scholar 

  6. Maehara Y, Kakeji Y, Watanabe A, Baba H, Kusumoto H, Kohnoe S, et al. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer. 1999;85:302–8.

    Article  PubMed  CAS  Google Scholar 

  7. Bourhis J, Lubin R, Roche B, Koscielny S, Bosq J, Dubois I, et al. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst. 1996;88:1228–33.

    Article  PubMed  CAS  Google Scholar 

  8. Gao RJ, Bao HZ, Yang Q, Cong Q, Song JN, Wang L. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters. Breast Cancer Res Treat. 2005;93:111–5.

    Article  PubMed  CAS  Google Scholar 

  9. Bao H, Yu D, Wang J, Qiu T, Yang J, Wang L. Predictive value of serum anti-p53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients. Anticancer Drugs. 2008;19:317–23.

    Article  PubMed  CAS  Google Scholar 

  10. Lenner P, Wiklund F, Emdin SO, Arnerlöv C, Eklund C, Hallmans G, et al. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study. Br J Cancer. 1999;79:927–32.

    Article  PubMed  CAS  Google Scholar 

  11. Japanese Breast Cancer Society. General rules for clinical and pathological recording of breast cancer. Breast Cancer. 2005;12:S12–4.

    Google Scholar 

  12. Sobin L, Gospodarowicz M, Wittekind C. International Union Against Cancer. TNM classification of malignant tumours. 7th ed. New York: Wiley-Blackwell; 2009. p. 73–7.

  13. Shimada H, Ochiai T, Nomura F, Japan p53 Antibody Research Group. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer. 2003;97:682–9.

    Article  PubMed  Google Scholar 

  14. Nishimura R, Arima N. Is triple negative a prognostic factor in breast cancer? Breast Cancer. 2008;15:303–8.

    Article  PubMed  Google Scholar 

  15. Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer. 1982;30:403–8.

    Article  PubMed  CAS  Google Scholar 

  16. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res. 1992;52:4168–74.

    PubMed  CAS  Google Scholar 

  17. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutation in the p53 gene occur in diverse human tumour types. Nature. 1989;342:705–8.

    Article  PubMed  CAS  Google Scholar 

  18. Lubin R, Zalcman G, Bouchet L, Tredanel J, Legros Y, Cazals D, et al. Serum p53 antibodies as early markers of lung cancer. Nat Med. 1995;1:701–2.

    Article  PubMed  CAS  Google Scholar 

  19. Angelopoulou K, Diamandis EP, Sutherland DJ, Kellen JA, Bunting PS. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer. 1994;58:480–7.

    Article  PubMed  CAS  Google Scholar 

  20. Balogh GA, Mailo DA, Corte MM, Roncoroni P, Nardi H, Vincent E, et al. Mutant p53 protein in serum could be used as a molecular marker in human breast cancer. Int J Oncol. 2006;28:995–1002.

    PubMed  CAS  Google Scholar 

  21. Sangrajrang S, Arpornwirat W, Cheirsilpa A, Thisuphakorn P, Kalalak A, Sornprom A, et al. Serum p53 antibodies in correlation to other biological parameters of breast cancer. Cancer Detect Prev. 2003;27:182–6.

    Article  PubMed  CAS  Google Scholar 

  22. Volkmann M, Sinn HP, Gaugel D, Frey M, Hajjar Y, Ludwig J, et al. Anti-p53 in breast cancer: concordance of different assay procedures and association with p53 antigen expression. Oncology. 2002;63:297–305.

    Article  PubMed  CAS  Google Scholar 

  23. Angelopoulou K, Yu H, Bharaj B, Giai M, Diamandis EP. p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer. Clin Biochem. 2000;33:53–62.

    Article  PubMed  CAS  Google Scholar 

  24. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer—current status and future directions. Ann Oncol. 2009;20:1913–27.

    Article  PubMed  CAS  Google Scholar 

  25. Nozoe T, Mori E, Iguchi T, Egashira A, Adachi E, Matsukuma A, et al. Immunohistochemical expression of epidermal growth factor receptor in breast cancer. Breast Cancer. 2010 [E-Pub ahead of print].

  26. Venkitaraman R. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features. Expert Rev Anticancer Ther. 2010;10:199–207.

    Article  PubMed  CAS  Google Scholar 

  27. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25–32.

    Article  PubMed  CAS  Google Scholar 

  28. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–74.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Fukuoka Higashi Medical Center, 1-1-1 Chidori, Koga, 811-3195, Japan

    Tadahiro Nozoe, Emiko Mori, Mayuko Kono, Tomohiro Iguchi, Takashi Maeda, Akito Matsukuma & Takahiro Ezaki

Authors
  1. Tadahiro Nozoe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emiko Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mayuko Kono
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tomohiro Iguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takashi Maeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Akito Matsukuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takahiro Ezaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tadahiro Nozoe.

About this article

Cite this article

Nozoe, T., Mori, E., Kono, M. et al. Serum appearance of anti-p53 antibody in triple negative breast cancer. Breast Cancer 19, 11–15 (2012). https://doi.org/10.1007/s12282-010-0244-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-010-0244-3

Keywords

Search

Navigation